Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 20, 2017 07:55 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Provide Corporate Updates at Upcoming Industry and Investment Conferences

FRAMINGHAM, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic...
September 12, 2017 07:55 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Reports Favorable Results in Repeat Dose Testing of AC5™ for Subchronic Systemic Toxicity

FRAMINGHAM, Mass., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices...
September 06, 2017 07:55 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Provide Corporate Update at the 19th Annual Rodman & Renshaw Global Investment Conference In New York City September 10-12, 2017

FRAMINGHAM, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
July 25, 2017 07:55 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5(TM) Topical Gel

FRAMINGHAM, MA--(Marketwired - Jul 25, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today...
June 06, 2017 12:25 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Presents Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017

FRAMINGHAM, MA--(Marketwired - Jun 6, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today...
May 22, 2017 07:57 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Provide Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017

FRAMINGHAM, MA--(Marketwired - May 22, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be...
March 06, 2017 07:57 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Provide Corporate Update at the 29th Annual Roth Conference on Monday, March 13, 2017

FRAMINGHAM, MA--(Marketwired - Mar 6, 2017) - Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and...
February 27, 2017 08:18 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Provide Corporate Update at the Maxim Group - Haitong Securities Healthcare Investor and Partnering Conference

FRAMINGHAM, MA--(Marketwired - Feb 27, 2017) - Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic...
February 21, 2017 09:08 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics, Inc. $6.1 Million Registered Direct Offering

FRAMINGHAM, MA--(Marketwired - Feb 21, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a developer of innovative materials as hemostatic and wound care devices, today...
February 16, 2017 11:05 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Provides Corporate Milestone Update, Including Anticipated Filing of 510(k) for AC5(TM)

FRAMINGHAM, MA--(Marketwired - Feb 16, 2017) - Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH), developer of innovative materials as hemostatic and wound care devices,...